Differential Expression of Maternal Plasma MicroRNAs and Their Respective Gene Targets Can Predict Early Fetal Growth Restriction

Overview

Journal Life (Basel)

Specialty Biology

Date 2025 Feb 26

PMID 40003576

Authors

Emmanuel Kolawole

Aparna Duggirala

Oscar Gronow

Agnieszka Wisniewska

Jiamiao Hu

Bee Kang Tan

Affiliations

Soon will be listed here.

Abstract

Fetal growth restriction (FGR) is a condition where the fetus does not reach its genetically predetermined size, affecting 1 in 10 pregnancies and contributing to up to 50% of all stillbirths before 34 weeks of gestation. Current diagnostic methods primarily involve ultrasound and Doppler assessments, yet there is growing interest in identifying biomarkers for early diagnosis and improved management. This systematic review examined the role of microRNAs (miRNAs) in the pathogenesis of FGR, focusing on their potential as non-invasive biomarkers. MicroRNAs are small, non-coding RNAs that regulate gene expression. This review systematically assessed studies investigating the differential expression of miRNAs in maternal blood, serum, and plasma samples from FGR-affected pregnancies. A total of nine studies met the inclusion criteria, which showed the differential expression of a total of 48 miRNAs. miR-16-5p was consistently upregulated in multiple studies and trimesters. miR-590-3p and miR-206 were consistently upregulated in multiple trimesters. The common gene targets of these miRNAs are VEGF, PIGF, and MMP9. The downregulation of these genes contributes to impaired angiogenesis, trophoblast invasion, placental function, and fetal growth.

References

Hromadnikova I, Kotlabova K, Doucha J, Dlouha K, Krofta L . Absolute and relative quantification of placenta-specific micrornas in maternal circulation with placental insufficiency-related complications. J Mol Diagn. 2012; 14(2):160-7. DOI: 10.1016/j.jmoldx.2011.11.003. View

Pei J, Li Y, Min Z, Dong Q, Ruan J, Wu J . MiR-590-3p and its targets VEGF, PIGF, and MMP9 in early, middle, and late pregnancy: their longitudinal changes and correlations with risk of fetal growth restriction. Ir J Med Sci. 2021; 191(3):1251-1257. DOI: 10.1007/s11845-021-02664-6. View

Baschat A . Fetal growth restriction - from observation to intervention. J Perinat Med. 2010; 38(3):239-46. DOI: 10.1515/jpm.2010.041. View

Lash G, Innes B, Drury J, Robson S, Quenby S, Bulmer J . Localization of angiogenic growth factors and their receptors in the human endometrium throughout the menstrual cycle and in recurrent miscarriage. Hum Reprod. 2011; 27(1):183-95. DOI: 10.1093/humrep/der376. View

Baker B, Lui S, Lorne I, Heazell A, Forbes K, Jones R . Sexually dimorphic patterns in maternal circulating microRNAs in pregnancies complicated by fetal growth restriction. Biol Sex Differ. 2021; 12(1):61. PMC: 8597318. DOI: 10.1186/s13293-021-00405-z. View

Bersinger N, Odegard R . Serum levels of macrophage colony stimulating, vascular endothelial, and placenta growth factor in relation to later clinical onset of pre-eclampsia and a small-for-gestational age birth. Am J Reprod Immunol. 2005; 54(2):77-83. DOI: 10.1111/j.1600-0897.2005.00290.x. View

Danielli M, Thomas R, Gillies C, Lambert D, Khunti K, Tan B . Soluble Vascular Adhesion Protein 1 (sVAP-1) as a biomarker for pregnancy complications: A pilot study. PLoS One. 2023; 18(5):e0284412. PMC: 10228776. DOI: 10.1371/journal.pone.0284412. View

Gallagher L, Bardill J, Sucharov C, Wright C, Karimpour-Fard A, Zarate M . Dysregulation of miRNA-mRNA expression in fetal growth restriction in a caloric restricted mouse model. Sci Rep. 2024; 14(1):5579. PMC: 10918062. DOI: 10.1038/s41598-024-56155-6. View

Tong S, Joy Kaituu-Lino T, Walker S, MacDonald T . Blood-based biomarkers in the maternal circulation associated with fetal growth restriction. Prenat Diagn. 2019; 39(11):947-957. DOI: 10.1002/pd.5525. View

10.

Whitehead C, Teh W, Walker S, Leung C, Larmour L, Tong S . Circulating MicroRNAs in maternal blood as potential biomarkers for fetal hypoxia in-utero. PLoS One. 2013; 8(11):e78487. PMC: 3839903. DOI: 10.1371/journal.pone.0078487. View

11.

Precazzini F, Detassis S, Imperatori A, Denti M, Campomenosi P . Measurements Methods for the Development of MicroRNA-Based Tests for Cancer Diagnosis. Int J Mol Sci. 2021; 22(3). PMC: 7865473. DOI: 10.3390/ijms22031176. View

12.

Savvidou M, Yu C, Harland L, Hingorani A, Nicolaides K . Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction. Am J Obstet Gynecol. 2006; 195(6):1668-73. DOI: 10.1016/j.ajog.2006.03.065. View

13.

Nardozza L, Caetano A, Zamarian A, Mazzola J, Silva C, Marcal V . Fetal growth restriction: current knowledge. Arch Gynecol Obstet. 2017; 295(5):1061-1077. DOI: 10.1007/s00404-017-4341-9. View

14.

Fineout-Overholt E, Melnyk B, Schultz A . Transforming health care from the inside out: advancing evidence-based practice in the 21st century. J Prof Nurs. 2005; 21(6):335-44. DOI: 10.1016/j.profnurs.2005.10.005. View

15.

Hromadnikova I, Kotlabova K, Ivankova K, Krofta L . First trimester screening of circulating C19MC microRNAs and the evaluation of their potential to predict the onset of preeclampsia and IUGR. PLoS One. 2017; 12(2):e0171756. PMC: 5300267. DOI: 10.1371/journal.pone.0171756. View

16.

Bao M, Li G, Huang X, Tang L, Dong L, Li J . Long Noncoding RNA LINC00657 Acting as a miR-590-3p Sponge to Facilitate Low Concentration Oxidized Low-Density Lipoprotein-Induced Angiogenesis. Mol Pharmacol. 2018; 93(4):368-375. DOI: 10.1124/mol.117.110650. View

17.

Schlembach D . Fetal Growth Restriction - Diagnostic Work-up, Management and Delivery. Geburtshilfe Frauenheilkd. 2020; 80(10):1016-1025. PMC: 7518933. DOI: 10.1055/a-1232-1418. View

18.

Zhu J, Zhong M, Pang Z, Yu Y . Dysregulated expression of matrix metalloproteinases and their inhibitors may participate in the pathogenesis of pre-eclampsia and fetal growth restriction. Early Hum Dev. 2014; 90(10):657-64. DOI: 10.1016/j.earlhumdev.2014.08.007. View

19.

Kingdom J, Huppertz B, Seaward G, Kaufmann P . Development of the placental villous tree and its consequences for fetal growth. Eur J Obstet Gynecol Reprod Biol. 2000; 92(1):35-43. DOI: 10.1016/s0301-2115(00)00423-1. View

20.

Zhang K, Zen M, Popovic N, Lee V, Alahakoon T . Urinary placental growth factor in preeclampsia and fetal growth restriction: An alternative to circulating biomarkers?. J Obstet Gynaecol Res. 2019; 45(9):1828-1836. DOI: 10.1111/jog.14038. View